TickerGuard
Buy Day today: Neutral (61) Mixed market breadth · no major macro event
RGC

Regencell Bioscience Holdings Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

5.40$ +3.4% vs. previous close Closing price · As of: Nov 11, 2026

Ownership

Ownership Structure

Who owns Regencell Bioscience Holdings Ltd (RGC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 11.2% of the shares are freely tradable; institutional investors hold 0.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 0.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 88.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 11.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 496Mio.

Largest Shareholders

Institutions

Institutions RGC
Name Stake (%) Shares Change (%) Date
Geode Capital Management, LLC 0.09 422,011 +1.6 06/30/2026
Alyeska Investment Group, L.P. 0.08 416,261 +0.0 06/30/2026
Legal & General Group PLC 0.03 128,000 +1,192.5 06/30/2026
Jane Street Group LLC 0.02 98,348 +0.0 06/30/2026
XTX Topco Ltd 0.01 60,061 +0.0 06/30/2026
Amundi 0.01 47,159 +448.7 06/30/2026
UBS Group AG 0.01 43,208 +80.9 06/30/2026
Quadrature Capital Limited 0.01 41,750 +0.0 06/30/2026

Funds

Funds RGC
Name Stake (%) Shares Change (%) Date
Fidelity Nasdaq Composite Index 0.06 301,859 +0.0 08/31/2026
Fidelity Nasdaq Composite ETF 0.02 122,516 +0.0 10/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?